OTC Switch Public Health Arguments Tougher In Light Of FDA Stance
This article was originally published in The Tan Sheet
Executive Summary
Public health arguments supporting OTC switches for chronic indications become more difficult in light of FDA's refusal to consider economic implications for switching second-generation antihistamines, a J&J/Merck rep said June 11.